With experience treating over 30,000 patients, our team spots patterns and takes action to prevent side effects from interfering with progress
Wegovy is now uniquely positioned as the first and only GLP-1 treatment approved for MASH, complementing the already proven weight loss, cardiovascular benefits and extensive body of evidence linked to semaglutide, said Martin Holst Lange, executive vice president, chief scientific officer and head of Research and Development, at Novo Nordisk
Its not publicly available, but the researchers and doctors are watching closely
At SMaRT Health & Wellness, we integrate cutting-edge medical advancements with personalized care to help optimize your health, longevity, and performance
Schedule a consultation today and take control of your psoriasis with confidence